Related Experiment Video

Updated: Oct 25, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.6K

Targeted radioactive therapy for prostate cancer

Ugo De Giorgi1, Vincenza Conteduca1, Giorgia Gurioli1

  • 1Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori-IRST-Dino Amadori, 47014 Meldola, Italy.

Lancet (London, England)
|August 8, 2021
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.3K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.4K

Related Experiment Videos

Last Updated: Oct 25, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.6K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.3K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K

Articles linked to this work by shared authors, journal, and citation graph.

Choline PET/CT in the PSMA Era: Clinical Repositioning, Biological Perspectives, and Emerging Applications.

Diagnostics (Basel, Switzerland)·2026

Correction: Endometrioid cancer associated with endometriosis: from the seed and soil theory to clinical practice.

Frontiers in oncology·2026

Prostate-Specific Membrane Antigen (PSMA): A Potential Theranostic Biomarker in Breast Cancer.

Biomedicines·2026

PSMA for HCC: a new frontier in precision medicine for liver cancer?

Cancer treatment and research communications·2026

Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor-targeting therapy.

Prostate cancer and prostatic diseases·2026

Impact of Circulating Tumor DNA and Copy-Number Alterations on Clinical Outcome in Relapsed/Refractory Germ Cell Tumors Treated With Salvage High-Dose Chemotherapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial.

Lancet (London, England)·2026

Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

Lancet (London, England)·2026

Psoriasis.

Lancet (London, England)·2026

Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial.

Lancet (London, England)·2026

Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study.

Lancet (London, England)·2026

Oral step-down, optimal drug, and total duration of antibiotic treatment in African children hospitalised with severe community-acquired pneumonia (PediCAP): a factorial randomised controlled trial.

Lancet (London, England)·2026

Overcoming Clinical Validation Challenges for an In Vitro Diagnostic Biodosimetry Test.

Military medicine·2026

Up to Four-Year Outcomes of Single-Fraction Stereotactic Radiosurgery for Small Brain Metastases: A Competing-Risk Analysis.

Cancer medicine·2026

Importance of performing SPECT/CT in thyroid Cancer patients with central neck uptake in whole body Iodine scan: A case report.

Asia Oceania journal of nuclear medicine & biology·2026

Prognostic factors and outcomes of CT-guided Iodine-125 seed brachytherapy for retroperitoneal lymph node metastases from a previously irradiated field in cervical carcinoma: a multicenter retrospective study.

Frontiers in oncology·2026

Evidence of different predictors for different types of cardiotoxicities after hypo-fractionated whole breast radiotherapy.

Frontiers in oncology·2026

Longitudinal multi-b-value diffusion MRI for the early assessment of radiation-induced parotid injury in nasopharyngeal carcinoma.

Frontiers in oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us